Anna Cecília Dias Maciel Carneiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna Cecília Dias Maciel Carneiro has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Virginia Oliveira Crema
Federal University of Triângulo Mineiro
7 shared publications - Helio Moraes-Souza
Medical Clinical Department, Institute of Health Sciences, Federal University of Triângulo Mineiro, Uberaba, MG, Brazil
6 shared publications - Fernanda Bernadelli De Vito
Universidade Federal do Triângulo Mineiro
5 shared publications - Lorraine Stephanie Hiss
Federal University of Triângulo Mineiro
4 shared publications - Sarah Cristina Sato Vaz Tanaka
Universidade Federal do Triângulo Mineiro
4 shared publications - Adilha Misson Rua Micheletti
Federal University of Triângulo Mineiro
2 shared publications
Latest Publications
- Open Access
- 30 May 2026
- Published by Editora RECIMA21 LTDA in RECIMA21 - Revista Científica Multidisciplinar
- Vol. 7 (6) , e768127
ANÁLISE DO POTENCIAL FARMACOLÓGICO DA EUPHORBIA UMBELLATA ALÉM DO CONTEXTO ONCOLÓGICO: UMA REVISÃO NARRATIVA DE APLICAÇÕES TERAPÊUTICAS
O uso de plantas medicinais tem se destacado como uma importante estratégia terapêutica complementar, especialmente em contextos de acessibilidade e no uso de práticas tradicionais. Nesse cenário, destaca-se a Euphorbia umbellata, amplamente utilizada na medicina popular brasileira, que embora apresente grande parte dos estudos voltados a sua atividade antineoplásica, a espécie possui um potencial farmacológico que se estende a outras aplicações terapêuticas. Assim, o presente estudo teve como objetivo reunir, avaliar e interpretar trabalhos científicos sobre o uso da Euphorbia umbellata em contextos não relacionados ao ambiente tumoral. Trata-se de uma revisão narrativa, de natureza qualitativa realizada a partir da análise de estudos disponíveis nas bases PubMed, SciElo e Google Acadêmico. Os resultados revelaram que a planta possui um amplo espectro de atividades biológicas, como ações anti-inflamatórias, antimicrobianas, analgésicas, imunomoduladoras, gastroprotetoras e vasculares. Estes efeitos estão associados, principalmente à presença de compostos bioativos como terpenoides e fenólicos. Apesar dos achados promissores, observa-se que a maioria dos estudos ainda se concentra em modelos experimentais in vivo e in vitro, o que limita sua aplicação clínica imediata. Dessa forma, ressalta-se a necessidade de investigações clínicas que consolidem sua eficácia e segurança, ampliando as possibilidades para o uso da espécie na prática terapêutica.
- 30 May 2026
- Published by Editora RECIMA21 LTDA in RECIMA21 - Revista Científica Multidisciplinar
- Vol. 7 (6) , e768127
Open AccessANÁLISE DO POTENCIAL FARMACOLÓGICO DA EUPHORBIA UMBELLATA ALÉM DO CONTEXTO ONCOLÓGICO: UMA REVISÃO NARRATIVA DE APLICAÇÕES TERAPÊUTICAS
O uso de plantas medicinais tem se destacado como uma importante estratégia terapêutica complementar, especialmente em contextos de acessibilidade e no uso de práticas tradicionais. Nesse cenário, destaca-se a Euphorbia umbellata, amplamente utilizada na medicina popular brasileira, que embora apresente grande parte dos estudos voltados a sua atividade antineoplásica, a espécie possui um potencial farmacológico que se estende a outras aplicações terapêuticas. Assim, o presente estudo teve como objetivo reunir, avaliar e interpretar trabalhos científicos sobre o uso da Euphorbia umbellata em contextos não relacionados ao ambiente tumoral. Trata-se de uma revisão narrativa, de natureza qualitativa realizada a partir da análise de estudos disponíveis nas bases PubMed, SciElo e Google Acadêmico. Os resultados revelaram que a planta possui um amplo espectro de atividades biológicas, como ações anti-inflamatórias, antimicrobianas, analgésicas, imunomoduladoras, gastroprotetoras e vasculares. Estes efeitos estão associados, principalmente à presença de compostos bioativos como terpenoides e fenólicos. Apesar dos achados promissores, observa-se que a maioria dos estudos ainda se concentra em modelos experimentais in vivo e in vitro, o que limita sua aplicação clínica imediata. Dessa forma, ressalta-se a necessidade de investigações clínicas que consolidem sua eficácia e segurança, ampliando as possibilidades para o uso da espécie na prática terapêutica.
- Open Access
- 3 February 2026
- Published by Wiley in Transfusion Medicine
- Vol. 36 (3) , 211-221
What is the best approach to blood transfusion in sickle cell disease? A scientometric analysis and literature review
Background: Blood transfusion remains a cornerstone in the management of sickle cell disease (SCD); however, it is frequently complicated by red cell alloimmunisation. A significant debate persists within the scientific community regarding the optimal strategy to mitigate this risk: the traditional, pragmatic approach of serologic phenotyping versus molecular genotyping, which is technically superior yet more resource‐intensive. Objectives: This mini‐review aims to map the framework of this scientific debate and synthesize current evidence through a dual methodology. Methods and Materials: A scientometric analysis was conducted on 224 articles indexed in Scopus and Web of Science using the Bibliometrix package for R, followed by a structured narrative review of 26 selected studies. Results: The scientometric findings confirm growing interest in this topic, identifying two distinct yet interconnected research clusters that reflect the ongoing dialectic between phenotyping and genotyping, with the latter emerging as a ‘hot topic’ over the past decade. The narrative synthesis highlights a predominance of evidence supporting genotyping as the most accurate approach to preventing alloimmunisation, particularly given the high prevalence of RH system variants in individuals with SCD. In contrast, cost‐effectiveness analyses and implementation studies underscore substantial financial and logistical barriers that favour a more pragmatic, stepwise approach. Conclusion: We conclude that the future of transfusion safety in SCD does not lie in a binary choice but rather in a synergistic and stratified integration of both strategies. Implementing protocols that target genotyping for high‐risk patients, while simultaneously optimising the use of extended phenotyping, represents the most promising pathway to balance safety, cost and accessibility—ultimately ensuring the best possible transfusion therapy for this vulnerable population.
- 3 February 2026
- Published by Wiley in Transfusion Medicine
- Vol. 36 (3) , 211-221
Open AccessWhat is the best approach to blood transfusion in sickle cell disease? A scientometric analysis and literature review
Background: Blood transfusion remains a cornerstone in the management of sickle cell disease (SCD); however, it is frequently complicated by red cell alloimmunisation. A significant debate persists within the scientific community regarding the optimal strategy to mitigate this risk: the traditional, pragmatic approach of serologic phenotyping versus molecular genotyping, which is technically superior yet more resource‐intensive. Objectives: This mini‐review aims to map the framework of this scientific debate and synthesize current evidence through a dual methodology. Methods and Materials: A scientometric analysis was conducted on 224 articles indexed in Scopus and Web of Science using the Bibliometrix package for R, followed by a structured narrative review of 26 selected studies. Results: The scientometric findings confirm growing interest in this topic, identifying two distinct yet interconnected research clusters that reflect the ongoing dialectic between phenotyping and genotyping, with the latter emerging as a ‘hot topic’ over the past decade. The narrative synthesis highlights a predominance of evidence supporting genotyping as the most accurate approach to preventing alloimmunisation, particularly given the high prevalence of RH system variants in individuals with SCD. In contrast, cost‐effectiveness analyses and implementation studies underscore substantial financial and logistical barriers that favour a more pragmatic, stepwise approach. Conclusion: We conclude that the future of transfusion safety in SCD does not lie in a binary choice but rather in a synergistic and stratified integration of both strategies. Implementing protocols that target genotyping for high‐risk patients, while simultaneously optimising the use of extended phenotyping, represents the most promising pathway to balance safety, cost and accessibility—ultimately ensuring the best possible transfusion therapy for this vulnerable population.
- 21 June 2025
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 64 (4) , 104177
Characterization of the practice of pretransfusion medication in the oncohematology unit and knowledge of physicians and nurses
- 21 June 2025
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 64 (4) , 104177
Characterization of the practice of pretransfusion medication in the oncohematology unit and knowledge of physicians and nurses
- Open Access
- 29 February 2024
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (2) , 186-191
Underreporting of transfusion incidents
- 29 February 2024
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (2) , 186-191
Open AccessUnderreporting of transfusion incidents
- Open Access
- 8 November 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (15)
Relation of TGF-β1 gene with the prognosis of patients with Covid-19
This study aimed to investigate the role of the TGF-β1 gene in SARS-CoV-2 infection. A total of 178 individuals diagnosed with Covid-19 participated and, they were divided in two groups related to the outcome (discharge or death). Genotyping of rs1800468 and rs1800469 polymorphisms of TGF-β1 gene was performed in 178 samples, using the allelic discrimination technique and, gene expression analysis was performed in 93 samples by Real Time PCR. There was no association between the genotypic frequencies of TGF-β1 gene polymorphisms analyzed with the prognosis of patients with Covid-19. There was no significant difference between gene expression and the clinical data evaluated. A statistically significant difference was observed in the expression of the TGF-β1 gene between the CT and TT genotypes of the rs1800469 polymorphism, with lower gene expression in the presence of the TT genotype. Regarding the rs1800468 polymorphism, no statistically significant difference was observed in the expression of the TGF-β1 gene in relation to the analyzed genotypes. The present study concluded that the rs1800468 and rs1800469 polymorphisms of the TGF-β1 gene are not associated with the prognosis of patients with Covid-19 and which the TT genotype of the rs1800469 polymorphism reduces the expression of TGF-β1.
- 8 November 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (15)
Open AccessRelation of TGF-β1 gene with the prognosis of patients with Covid-19
This study aimed to investigate the role of the TGF-β1 gene in SARS-CoV-2 infection. A total of 178 individuals diagnosed with Covid-19 participated and, they were divided in two groups related to the outcome (discharge or death). Genotyping of rs1800468 and rs1800469 polymorphisms of TGF-β1 gene was performed in 178 samples, using the allelic discrimination technique and, gene expression analysis was performed in 93 samples by Real Time PCR. There was no association between the genotypic frequencies of TGF-β1 gene polymorphisms analyzed with the prognosis of patients with Covid-19. There was no significant difference between gene expression and the clinical data evaluated. A statistically significant difference was observed in the expression of the TGF-β1 gene between the CT and TT genotypes of the rs1800469 polymorphism, with lower gene expression in the presence of the TT genotype. Regarding the rs1800468 polymorphism, no statistically significant difference was observed in the expression of the TGF-β1 gene in relation to the analyzed genotypes. The present study concluded that the rs1800468 and rs1800469 polymorphisms of the TGF-β1 gene are not associated with the prognosis of patients with Covid-19 and which the TT genotype of the rs1800469 polymorphism reduces the expression of TGF-β1.
- Open Access
- 13 May 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (7)
Effect of chronic alcoholism on morphology and cell proliferation in salivary glands of Wistar rats
Several disorders which affect the oral cavity, salivary composition and, flow have been described in alcoholics chronic, thus this study aimed to evaluate the effects of chronic alcoholism on the salivary glands of Wistar rats. It was used 18 animals randomly subdivided into two groups: control (C) and treated with ethanol (T). C group (n=9) received water ad libitum and T group (n=9) received alcoholic solution ad libitum: 5% ethanol (1st week), 10% ethanol (2nd week) and 20% ethanol (for 9 weeks). After the treatment period, the animals were anesthetized and euthanized by decapitation. The parotid, submandibular and sublingual salivary glands of both groups were dissected, fixed and processed for paraffin. Histological sections were stained with hematoxylin/eosin and Picro-Sirius red stained, and the rate of cell proliferation was determined by immunohistochemistry with the marker KI-67. The salivary glands of group C showed preserved parenchyma, while the parotid and submandibular glands of group T showed hydropic degeneration, atypical nuclei, non-evident nucleolus and condensed chromatin in serous acini. The intercalated, striated and excretory ducts were seen with punctual areas of degeneration and nuclear atypia. In the submandibular glands there was a 73% increase in proliferative cells in T, when compared to C (p<0.05). However, in the parotid glands, there was no significant difference in the rate of cell proliferation. The results suggest that there is an increase in the rate of cell proliferation in submandibular glands of Wistar rats subjected to chronic alcohol consumption, and also show that chronic alcohol consumption promotes morphological changes in the salivary glands of these rats, causing a deleterious effect on cellular structures.
- 13 May 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (7)
Open AccessEffect of chronic alcoholism on morphology and cell proliferation in salivary glands of Wistar rats
Several disorders which affect the oral cavity, salivary composition and, flow have been described in alcoholics chronic, thus this study aimed to evaluate the effects of chronic alcoholism on the salivary glands of Wistar rats. It was used 18 animals randomly subdivided into two groups: control (C) and treated with ethanol (T). C group (n=9) received water ad libitum and T group (n=9) received alcoholic solution ad libitum: 5% ethanol (1st week), 10% ethanol (2nd week) and 20% ethanol (for 9 weeks). After the treatment period, the animals were anesthetized and euthanized by decapitation. The parotid, submandibular and sublingual salivary glands of both groups were dissected, fixed and processed for paraffin. Histological sections were stained with hematoxylin/eosin and Picro-Sirius red stained, and the rate of cell proliferation was determined by immunohistochemistry with the marker KI-67. The salivary glands of group C showed preserved parenchyma, while the parotid and submandibular glands of group T showed hydropic degeneration, atypical nuclei, non-evident nucleolus and condensed chromatin in serous acini. The intercalated, striated and excretory ducts were seen with punctual areas of degeneration and nuclear atypia. In the submandibular glands there was a 73% increase in proliferative cells in T, when compared to C (p<0.05). However, in the parotid glands, there was no significant difference in the rate of cell proliferation. The results suggest that there is an increase in the rate of cell proliferation in submandibular glands of Wistar rats subjected to chronic alcohol consumption, and also show that chronic alcohol consumption promotes morphological changes in the salivary glands of these rats, causing a deleterious effect on cellular structures.
- Open Access
- 6 February 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (3)
HA1077 inhibits cell proliferation of oral squamous cell carcinoma in vitro
Oral squamous cell carcinoma is a common malignant lesion. ROCKs proteins are associated with pathogenesis and progression of human tumours. This study aimed to evaluate the functional role of ROCKs in the regulation of cell proliferation of oral squamous cell carcinoma in vitro. BrdU incorporation assays and KI-67 immunoexpression were performed by using SCC-4 cell line from oral squamous cell carcinoma. Control and treated cells: HA-1077 (25, 50 and 100 μmol/l), 50 μmol HA-1077 and Y-27632 30 μmol/l, Y-27632 30 μmol/l were cutured for 6 h. The number of SCC-4 cells treated with: HA-1077 (25, 50 and 100 μmol/l), HA-1077 50 μmol/l and/or Y-27632 30 μmol/l was significantly lower than control cells in BrdU assay [F (5.17) = 443.818, p<0.0001] and in KI-67 assay [F = 192.595, d.f. = 5,17; p<0.0001]. The results obtained suggest that the pathways that evolve ROCKs proteins play an important functional role in the positive regulation of cell proliferation in oral squamous cell carcinoma.
- 6 February 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (3)
Open AccessHA1077 inhibits cell proliferation of oral squamous cell carcinoma in vitro
Oral squamous cell carcinoma is a common malignant lesion. ROCKs proteins are associated with pathogenesis and progression of human tumours. This study aimed to evaluate the functional role of ROCKs in the regulation of cell proliferation of oral squamous cell carcinoma in vitro. BrdU incorporation assays and KI-67 immunoexpression were performed by using SCC-4 cell line from oral squamous cell carcinoma. Control and treated cells: HA-1077 (25, 50 and 100 μmol/l), 50 μmol HA-1077 and Y-27632 30 μmol/l, Y-27632 30 μmol/l were cutured for 6 h. The number of SCC-4 cells treated with: HA-1077 (25, 50 and 100 μmol/l), HA-1077 50 μmol/l and/or Y-27632 30 μmol/l was significantly lower than control cells in BrdU assay [F (5.17) = 443.818, p<0.0001] and in KI-67 assay [F = 192.595, d.f. = 5,17; p<0.0001]. The results obtained suggest that the pathways that evolve ROCKs proteins play an important functional role in the positive regulation of cell proliferation in oral squamous cell carcinoma.
- Open Access
- 23 October 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (14)
Comparison of the use of Solidago chilensis (Arnica) and low-level laser therapy for the prevention of oral mucositis in patients submitted of head and neck radiotherapy and/or high toxicity chemotherapy
The oral mucositis is an adverse event of radiotherapy and/or high toxicity chemotherapy. The Solidago chilensis (Arnica) has been used for its antiseptic, analgesic, healing and anti-inflammatory properties. Objective: The purpose of this study was to evaluate the uses of Arnica for oral mucositis prevention in patients submitted to radiotherapy for head and neck tumors treatment and/or high toxicity chemotherapy. Methodology: The determination of the cytotoxicity index of the aqueous extract was determined in vitro. The oral mucosa was evaluated in days 0, 10 and 14 of patients in the groups: treated with lasertherapy (L, n=18), treated with Arnica (A, n=24) and, treated with lasertherapy associated with Arnica (LA, n=4). It was considered significant p<0.05. Results: It was determined IC50=90,74 μg/mL of Arnica’s aqueous extract in SCC-4 cells. The development of oral mucositis was associated with the type of treatment for oral mucositis prevention: L, A, and LA (χ2 = 24,72, p<0.0001). The level of oral mucositis had significant interaction with the type of prevention treatment [F(2) = 9.545, p<0.0001] and, within 14 days [F(2) = 11.995, p<0.0001]. Conclusions: The results obtained suggest which the use of Solidago chilensis (Arnica) can be an important therapeutic option for treatment with low-level laser therapy for oral mucositis prevention in patients submitted of head and neck radiotherapy and/or high toxicity chemotherapy.
- 23 October 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (14)
Open AccessComparison of the use of Solidago chilensis (Arnica) and low-level laser therapy for the prevention of oral mucositis in patients submitted of head and neck radiotherapy and/or high toxicity chemotherapy
The oral mucositis is an adverse event of radiotherapy and/or high toxicity chemotherapy. The Solidago chilensis (Arnica) has been used for its antiseptic, analgesic, healing and anti-inflammatory properties. Objective: The purpose of this study was to evaluate the uses of Arnica for oral mucositis prevention in patients submitted to radiotherapy for head and neck tumors treatment and/or high toxicity chemotherapy. Methodology: The determination of the cytotoxicity index of the aqueous extract was determined in vitro. The oral mucosa was evaluated in days 0, 10 and 14 of patients in the groups: treated with lasertherapy (L, n=18), treated with Arnica (A, n=24) and, treated with lasertherapy associated with Arnica (LA, n=4). It was considered significant p<0.05. Results: It was determined IC50=90,74 μg/mL of Arnica’s aqueous extract in SCC-4 cells. The development of oral mucositis was associated with the type of treatment for oral mucositis prevention: L, A, and LA (χ2 = 24,72, p<0.0001). The level of oral mucositis had significant interaction with the type of prevention treatment [F(2) = 9.545, p<0.0001] and, within 14 days [F(2) = 11.995, p<0.0001]. Conclusions: The results obtained suggest which the use of Solidago chilensis (Arnica) can be an important therapeutic option for treatment with low-level laser therapy for oral mucositis prevention in patients submitted of head and neck radiotherapy and/or high toxicity chemotherapy.
- Open Access
- 18 July 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (9)
Red Blood Cell Distribution Width (RDW) as a prognostic marker for COVID-19: A literature review
The Red Cell Distribution Width (RDW) is a component of blood count which gives the variation of erythrocytes, used in laboratory hematology. The analysis of this parameter is in evidence, as the increased levels of RDW seem to be a mortality predictor. The infections of the respiratory tract are in these conditions and the increase of RDW has already been related to severe acute respiratory syndrome (SARS). In December of 2019, the first cases of severe acute pneumonia caused by the SARS-CoV-2 virus emerged in China. The Corona Virus Disease-19 (COVID-19) has as most common clinical manifestations changes in the respiratory tract that range from mild to severe symptoms, requiring respiratory support in severe cases. Current evidence point to the increase of RDW value which is related to severity of the disease and mortality rates due to COVID-19. The large number of severe cases of COVID-19 shows the urgent of the identification of cheap diagnostic parameters and easy detection, which could be used for determining the prognosis of these patients. The RDW has been shown to be a potential biomarker due to the easy obtaining, low cost, and therefore, it can be an important guide to early and effective interventions.
- 18 July 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (9)
Open AccessRed Blood Cell Distribution Width (RDW) as a prognostic marker for COVID-19: A literature review
The Red Cell Distribution Width (RDW) is a component of blood count which gives the variation of erythrocytes, used in laboratory hematology. The analysis of this parameter is in evidence, as the increased levels of RDW seem to be a mortality predictor. The infections of the respiratory tract are in these conditions and the increase of RDW has already been related to severe acute respiratory syndrome (SARS). In December of 2019, the first cases of severe acute pneumonia caused by the SARS-CoV-2 virus emerged in China. The Corona Virus Disease-19 (COVID-19) has as most common clinical manifestations changes in the respiratory tract that range from mild to severe symptoms, requiring respiratory support in severe cases. Current evidence point to the increase of RDW value which is related to severity of the disease and mortality rates due to COVID-19. The large number of severe cases of COVID-19 shows the urgent of the identification of cheap diagnostic parameters and easy detection, which could be used for determining the prognosis of these patients. The RDW has been shown to be a potential biomarker due to the easy obtaining, low cost, and therefore, it can be an important guide to early and effective interventions.
- Open Access
- 18 July 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (9)
Potential therapy with the inhibitor of TGF-β receptors LY2109761 for oral squamous cell carcinoma
One way of trying to control oral squamous cell carcinoma is to invest in new therapies focused on the molecular biology of receptors and their intracellular signaling pathways. This study aimed to evaluate the effect of LY2109761 (an inhibitor of TGF-β receptors) on cell migration in oral squamous cell carcinoma in vitro. Actin cytoskeleton of SCC-4 cells control and LY2109761 (1, 5 and 10 μM) treated on three-dimensional Matrigel were analysed by using confocal laser microscopy. Control and LY2109761 (1, 5 and 10 μM) treated cells that migrated through the membrane of three-dimensional cell migration assays were counted, significance was p<0.05. Control cells were seen with voluminous cytoplasm, cell cortex preserved and actin cytoskeleton well developed with well distributed actin filaments. Regardless of concentration, cells treated showed: rounded morphology and small size, scanty cytoplasm, cortical F-actin less clear that the control cells, and disruption of actin filaments. The migratory cells were inhibited by treatment with LY2109761 [F (3, 11) = 3742, p<0.0001], in a dose-dependent manner. These results suggest that LY2109761 exerts an inhibitory effect on the actin cytoskeleton and cell migration on SCC-4 cells, therefore, it is a promising therapeutic option for oral squamous cell carcinoma.
- 18 July 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (9)
Open AccessPotential therapy with the inhibitor of TGF-β receptors LY2109761 for oral squamous cell carcinoma
One way of trying to control oral squamous cell carcinoma is to invest in new therapies focused on the molecular biology of receptors and their intracellular signaling pathways. This study aimed to evaluate the effect of LY2109761 (an inhibitor of TGF-β receptors) on cell migration in oral squamous cell carcinoma in vitro. Actin cytoskeleton of SCC-4 cells control and LY2109761 (1, 5 and 10 μM) treated on three-dimensional Matrigel were analysed by using confocal laser microscopy. Control and LY2109761 (1, 5 and 10 μM) treated cells that migrated through the membrane of three-dimensional cell migration assays were counted, significance was p<0.05. Control cells were seen with voluminous cytoplasm, cell cortex preserved and actin cytoskeleton well developed with well distributed actin filaments. Regardless of concentration, cells treated showed: rounded morphology and small size, scanty cytoplasm, cortical F-actin less clear that the control cells, and disruption of actin filaments. The migratory cells were inhibited by treatment with LY2109761 [F (3, 11) = 3742, p<0.0001], in a dose-dependent manner. These results suggest that LY2109761 exerts an inhibitory effect on the actin cytoskeleton and cell migration on SCC-4 cells, therefore, it is a promising therapeutic option for oral squamous cell carcinoma.